{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from Bio import Medline\n",
    "from Bio import Entrez"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "term = \"Bacteremia and Sepsis Hagel S\"\n",
    "\n",
    "Entrez.max_tries=5\n",
    "Entrez.email=\"\" # Necesario o error\n",
    "\n",
    "scout_search = Entrez.esearch(db=\"pubmed\", rettype=\"count\", term = term)\n",
    "scout_result = Entrez.read(scout_search)\n",
    "id_quantity = int(scout_result[\"Count\"])\n",
    "message = f\"La cantidad de resultados es {id_quantity} para el término de búsqueda \\\"{term}\\\".\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "La cantidad de resultados es 12 para el término de búsqueda \"Bacteremia and Sepsis Hagel S\".\n"
     ]
    }
   ],
   "source": [
    "print(message)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'PMID': '31504603', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20200925', 'LR': '20200925', 'IS': '1460-2091 (Electronic) 0305-7453 (Linking)', 'VI': '74', 'IP': '12', 'DP': '2019 Dec 1', 'TI': 'Clinimetric properties and suitability of selected quality indicators for assessing antibiotic use in hospitalized adults: a multicentre point prevalence study in 24 hospitals in Germany.', 'PG': '3596-3602', 'LID': '10.1093/jac/dkz364 [doi]', 'AB': 'OBJECTIVES: The capability to measure and monitor the quality of antibiotic prescribing is an important component of antibiotic stewardship (ABS) programmes. Several catalogues of consensus-based structure and process-of-care quality indicators (QIs) have been proposed, but only a few studies have tested and validated ABS QIs in practice tests. This multicentre study determined the clinimetric properties and suitability of a set of 33 process QIs for ABS that had earlier been developed and in part recommended in a German-Austrian hospital ABS practice guideline. METHODS: Two point prevalence surveys were conducted in a convenience sample of 24 acute care hospitals throughout Germany, and data of all screened adult inpatients with prescription of a systemic antibiotic at a given day (n=4310) were included in the study. For each QI, the following clinimetric properties were assessed: applicability, feasibility, performance, case mix stability and interobserver reliability. RESULTS: Eighteen QIs were considered sufficiently feasible, applicable and reliable, and had adequate room for improvement. The finally selected QIs primarily cover antibiotic therapy of common infections (bloodstream infection, pneumonia and urinary tract infection), while two of the QIs each address surgical prophylaxis and general aspects of antibiotic administration. CONCLUSIONS: Practice tests may be important to test the suitability of consensus process-of-care QIs in the field of hospital ABS. The 18 selected QIs considered suitable enough for hospital ABS in this study should be regarded as priority QIs useful for internal quality control and assurance. More research and additional practice tests may be needed to confirm their suitability for external quality assessment schemes.', 'CI': ['(c) The Author(s) 2019. Published by Oxford University Press on behalf of the', 'British Society for Antimicrobial Chemotherapy. All rights reserved. For', 'permissions, please email: journals.permissions@oup.com.'], 'FAU': ['Forst, Gesche', 'Kern, Winfried V', 'Weber, Nadine', 'Querbach, Christiane', 'Kleideiter, Johannes', 'Knoth, Holger', 'Hagel, Stefan', 'Ambrosch, Andreas', 'Lobermann, Micha', 'Schroder, Philipp', 'Borde, Johannes', 'Steib-Bauert, Michaela', 'de With, Katja'], 'AU': ['Forst G', 'Kern WV', 'Weber N', 'Querbach C', 'Kleideiter J', 'Knoth H', 'Hagel S', 'Ambrosch A', 'Lobermann M', 'Schroder P', 'Borde J', 'Steib-Bauert M', 'de With K'], 'AD': ['Division of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, Freiburg, Germany.', 'Pharmacy Service, University Hospital and Medical Center, Freiburg, Germany.', 'Division of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, Freiburg, Germany.', 'Albert-Ludwigs-University Faculty of Medicine, Freiburg, Germany.', 'Division of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, Freiburg, Germany.', \"Pharmacy, 'Rechts der Isar' Hospital of the Technical University, Munich, Germany.\", 'Infection Control Division, Bielefeld Clinical Center, Bielefeld, Germany.', 'Pharmacy Service, Medical Center Carl Gustav Carus University at the Technical University, Dresden, Germany.', 'Center for Infection and Infection Control, University Hospital, Jena, Germany.', \"Department of Laboratory Medicine, Microbiology and Infection Control, 'Barmherzige Bruder' Hospital, Regensburg, Germany.\", 'Department of Infectious Diseases and Tropical Medicine, University Medical Center, Rostock, Germany.', 'Department of Medicine, Federal Armed Forces Hospital, Ulm, Germany.', 'Division of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, Freiburg, Germany.', 'Infectious Diseases Section, Ortenau-Klinikum, Achern-Oberkirch, Germany.', 'Division of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, Freiburg, Germany.', 'Division of Infectious Diseases, University Hospital Carl Gustav Carus, Technische Universitat Dresden, Dresden, Germany.'], 'CN': ['ABS-QI Study Group'], 'LA': ['eng'], 'PT': ['Journal Article', 'Multicenter Study', \"Research Support, Non-U.S. Gov't\"], 'PL': 'England', 'TA': 'J Antimicrob Chemother', 'JT': 'The Journal of antimicrobial chemotherapy', 'JID': '7513617', 'RN': ['0 (Anti-Bacterial Agents)'], 'SB': 'IM', 'MH': ['Aged', 'Anti-Bacterial Agents/*therapeutic use', '*Antimicrobial Stewardship', 'Bacteremia/drug therapy/epidemiology', 'Cross-Sectional Studies', 'Drug Prescriptions/*statistics & numerical data', 'Female', 'Germany', 'Hospitals/*statistics & numerical data', 'Humans', 'Inpatients', 'Male', 'Middle Aged', 'Pilot Projects', 'Prevalence', '*Quality Indicators, Health Care', 'Quality of Health Care', 'Reproducibility of Results', 'Urinary Tract Infections/drug therapy/epidemiology/microbiology'], 'IR': ['Binesch F', 'Clausing B', 'Devide A', 'Donat M', 'Endler K', 'Feihl S', 'Freidank A', 'Fruchtel-Unterholzner E', 'Godde N', 'Grundel R', 'Grzibiela W', 'Kaiser R', 'Kawecki P', 'Kohlbrenner S', 'Lerner J', 'Lors E', 'Muller M', 'Papathanasiou N', 'Peltroche H', 'Probst W', 'Putzbach J', 'Reimer M', 'Reinwald AC', 'Rusche R', 'Scheerer M', 'Schulz C', 'Zessin E'], 'FIR': ['Binesch, Faranak', 'Clausing, Beate', 'Devide, Anette', 'Donat, Martina', 'Endler, Katja', 'Feihl, Susanne', 'Freidank, Annette', 'Fruchtel-Unterholzner, Edeltraud', 'Godde, Norbert', 'Grundel, Ralf', 'Grzibiela, Wolfgang', 'Kaiser, Rene', 'Kawecki, Piotr', 'Kohlbrenner, Stefan', 'Lerner, Johanna', 'Lors, Edeltraud', 'Muller, Matthias', 'Papathanasiou, Nikolas', 'Peltroche, Heidrun', 'Probst, Wiltrud', 'Putzbach, Jens', 'Reimer, Marion', 'Reinwald, Ann-Christin', 'Rusche, Ruth', 'Scheerer, Martin', 'Schulz, Claudia', 'Zessin, Enrico'], 'EDAT': '2019/09/11 06:00', 'MHDA': '2020/09/26 06:00', 'CRDT': ['2019/09/11 06:00'], 'PHST': ['2019/04/05 00:00 [received]', '2019/07/16 00:00 [revised]', '2019/07/24 00:00 [accepted]', '2019/09/11 06:00 [pubmed]', '2020/09/26 06:00 [medline]', '2019/09/11 06:00 [entrez]'], 'AID': ['5553749 [pii]', '10.1093/jac/dkz364 [doi]'], 'PST': 'ppublish', 'SO': 'J Antimicrob Chemother. 2019 Dec 1;74(12):3596-3602. doi: 10.1093/jac/dkz364.'}\n",
      "{'PMID': '30928559', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20191104', 'LR': '20191104', 'IS': '1469-0691 (Electronic) 1198-743X (Linking)', 'VI': '25', 'IP': '7', 'DP': '2019 Jul', 'TI': 'Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia.', 'PG': '818-827', 'LID': 'S1198-743X(19)30112-0 [pii] 10.1016/j.cmi.2019.03.010 [doi]', 'AB': 'BACKGROUND: For patients with bacteraemia caused by methicillin-sensitive Staphylococcus aureus anti-staphylococcal penicillins (ASPs) or cefazolin are agents of choice. While ASPs are potentially nephrotoxic, cefazolin may be less effective in some S. aureus strains due to an inoculum effect. OBJECTIVES: To perform a systematic literature review and meta-analysis assessing current evidence comparing cefazolin with ASPs for patients with S. aureus bacteraemia (SAB). METHODS: We searched MEDLINE, ISI Web of Science (Science Citation Index Expanded) and the Cochrane Database as well as clinicaltrials.gov from inception to 26 June 2018. All studies investigating the effects of cefazolin versus ASP in patients with methicillin-sensitive SAB were eligible for inclusion regardless of study design, publication status or language. Additional information was requested by direct author contact. A meta-analysis to estimate relative risks (RRs) with the corresponding 95% confidence intervals (CIs) was performed. Statistical heterogeneity was estimated using I(2). The primary endpoint was 90-day all-cause mortality. The Newcastle-Ottawa Scale (NOS) and Grading of Recommendations Assessment, Development and Evaluation (GRADE) were used for study and data quality assessment. RESULTS: Fourteen non-randomized studies were included. Seven reported the primary endpoint (RR 0.71 (0.50, 1.02), low quality of evidence). Cefazolin treatment may be associated with lower 30-day mortality rates (RR 0.70 (0.54, 0.91), low quality of evidence) and less nephrotoxicity (RR 0.36 (0.21, 0.59), (low quality of evidence)). We are uncertain whether cefazolin and ASP differ regarding treatment failure/relapse as the quality of the evidence has been assessed as very low (RR of 0.84 (0.59, 1.18)). For patients with endocarditis (RR 0.71 (0.12, 4.05)) or abscesses (RR 1.17 (0.30, 4.63)), cefazolin treatment may be associated with equal 30-day and 90-day mortality (low quality of evidence). CONCLUSIONS: Cefazolin seemed to be at least equally as effective as ASPs while being associated with less nephrotoxicity.', 'CI': ['Copyright (c) 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.'], 'FAU': ['Weis, S', 'Kesselmeier, M', 'Davis, J S', 'Morris, A M', 'Lee, S', 'Scherag, A', 'Hagel, S', 'Pletz, M W'], 'AU': ['Weis S', 'Kesselmeier M', 'Davis JS', 'Morris AM', 'Lee S', 'Scherag A', 'Hagel S', 'Pletz MW'], 'AD': ['Institute for Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany; Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany; Department of Anesthesiology and Intensive Care, Jena University Hospital, Jena, Germany. Electronic address: sebastian.weis@med.uni-jena.de.', 'Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany; Research Group Clinical Epidemiology, CSCC, Jena University Hospital, Jena, Germany.', 'Global and Tropical Health Division, Menzies School of Health Research, Darwin, NT, Australia; Department of Infectious Diseases, John Hunter Hospital, Newcastle, NSW, Australia.', 'Department of Medicine, Division of Infectious Diseases, Sinai Health System, University Health Network, University of Toronto, Canada.', 'Department of Internal Medicine, Pusan National University School of Medicine and Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.', 'Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany; Research Group Clinical Epidemiology, CSCC, Jena University Hospital, Jena, Germany; Institute of Medical Statistics, Computer and Data Sciences, Jena University Hospital, Jena, Germany.', 'Institute for Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany; Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany.', 'Institute for Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany.'], 'LA': ['eng'], 'PT': ['Journal Article', 'Meta-Analysis', 'Systematic Review'], 'DEP': '20190327', 'PL': 'England', 'TA': 'Clin Microbiol Infect', 'JT': 'Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases', 'JID': '9516420', 'RN': ['0 (Anti-Bacterial Agents)', '0 (Penicillins)', 'IHS69L0Y4T (Cefazolin)'], 'SB': 'IM', 'CIN': ['Clin Microbiol Infect. 2020 Feb;26(2):258-259. PMID: 31330190'], 'MH': ['Anti-Bacterial Agents/*therapeutic use', 'Bacteremia/*drug therapy', 'Cefazolin/*therapeutic use', 'Humans', 'Penicillins/*therapeutic use', 'Staphylococcal Infections/*drug therapy', 'Staphylococcus aureus/*drug effects', 'Treatment Failure'], 'OTO': ['NOTNLM'], 'OT': ['Anti-staphylococcal penicillins', 'Antimicrobial therapy', 'Bacteraemia', 'Cefazolin', 'Flucloxacillin', 'Meta-analysis', 'Staphylococcus aureus'], 'EDAT': '2019/04/01 06:00', 'MHDA': '2019/11/05 06:00', 'CRDT': ['2019/04/01 06:00'], 'PHST': ['2018/10/21 00:00 [received]', '2019/03/02 00:00 [revised]', '2019/03/09 00:00 [accepted]', '2019/04/01 06:00 [pubmed]', '2019/11/05 06:00 [medline]', '2019/04/01 06:00 [entrez]'], 'AID': ['S1198-743X(19)30112-0 [pii]', '10.1016/j.cmi.2019.03.010 [doi]'], 'PST': 'ppublish', 'SO': 'Clin Microbiol Infect. 2019 Jul;25(7):818-827. doi: 10.1016/j.cmi.2019.03.010. Epub 2019 Mar 27.'}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'PMID': '30866024', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20191003', 'LR': '20191007', 'IS': '1439-1074 (Electronic) 0939-2661 (Linking)', 'VI': '54', 'IP': '3', 'DP': '2019 Mar', 'TI': '[Staphylococcus aureus Bacteraemia - an Interdisciplinary Challenge].', 'PG': '206-216', 'LID': '10.1055/a-0756-8263 [doi]', 'AB': 'BACKGROUND: Staphylococcus aureus is the second-most-common pathogen among bloodstream infections. Due to a high hospital mortality rate (15 - 40%), frequent complications and recurrences the clinical management of Staphylococcus aureus bacteremia (SAB) is distinct from bacteremia from other pathogens. METHODS: A literature search was performed using PubMed. Guidelines and best practice expert recommendations were included. RESULTS: The detection of S. aureus in blood culture should always be considered clinically relevant. The drug of choice for treatment of a bloodstream infection with methicillin-sensitive S. aureus is flucloxacillin (8 - 12 g i. v./d). In a bloodstream infection with methicillin-resistant S. aureus (MRSA) vancomycin or daptomycin (the latter not in pneumonic focus) are recommended. Follow-up blood cultures, source identification, including transoesophageal echocardiography in patients with risk profile, and rapid source control are important measures. The duration of therapy is at least 14 days with uncomplicated SAB, whereby the entire therapy should be carried out intravenously. In case of complicated SAB, a total therapy duration of at least 4 - 6 weeks is recommended. Adherence to this set of measures can reduce mortality by up to 50%. CONCLUSION: SAB is associated with high morbidity and mortality. Clinical management is complex. By adhering to diagnostic and therapeutic measures, the prognosis can be improved.', 'CI': ['Georg Thieme Verlag KG Stuttgart . New York.'], 'FAU': ['Hagel, Stefan', 'Kaasch, Achim J', 'Weis, Sebastian', 'Seifert, Harald', 'Pletz, Mathias W', 'Rieg, Siegbert'], 'AU': ['Hagel S', 'Kaasch AJ', 'Weis S', 'Seifert H', 'Pletz MW', 'Rieg S'], 'LA': ['ger'], 'PT': ['Journal Article'], 'TT': 'Staphylococcus-aureus-Blutstrominfektion - eine interdisziplinare Herausforderung.', 'DEP': '20190313', 'PL': 'Germany', 'TA': 'Anasthesiol Intensivmed Notfallmed Schmerzther', 'JT': 'Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS', 'JID': '9109478', 'RN': ['0 (Anti-Bacterial Agents)'], 'SB': 'IM', 'MH': ['Anti-Bacterial Agents/therapeutic use', '*Bacteremia/drug therapy/microbiology', 'Humans', '*Methicillin-Resistant Staphylococcus aureus/pathogenicity', '*Staphylococcal Infections/drug therapy', 'Staphylococcus aureus'], 'COIS': ['Dr. med. Stefan Hagel hat Vortrags- und Beratungshonorare von Pfizer, MSD und', 'InfectoPharm erhalten. Univ.-Prof. Dr. med. Achim Kaasch hat Vortragshonorare von', 'Biomerieux, BD Biosciences, ViiV Healthcare, MSD Sharp and Dohme, Limbach Gruppe', 'SE, sowie Reiseunterstutzung von Janssen-Cilag erhalten. Er hat ohne Honorar an', 'Advisory Board Meetings der Firma XBiotech teilgenommen. PD Dr. med. Sebastian', 'Weis hat Vortragshonorare von MSD und InfectoPharm erhalten. Prof. Dr. med.', 'Harald Seifert hat Vortrags- und Beratungshonorare von Astellas, Basilea, Cubist,', 'Durata Gilead, InfectoPharm, MSD, Novartis, Roche Pharma und Tetraphase erhalten.', 'Prof. Dr. med. Mathias Pletz hat an nationalen und internationalen Advisory', 'Boards von Pfizer, Novartis, Basilea, InfectoPharm und Cubist teilgenommen und', 'Vortragshonorare dieser Firmen erhalten. Prof. Dr. med. Siegbert Rieg hat', 'Vortragshonorare von Pfizer und MSD erhalten.'], 'EDAT': '2019/03/14 06:00', 'MHDA': '2019/10/08 06:00', 'CRDT': ['2019/03/14 06:00'], 'PHST': ['2019/03/14 06:00 [entrez]', '2019/03/14 06:00 [pubmed]', '2019/10/08 06:00 [medline]'], 'AID': ['10.1055/a-0756-8263 [doi]'], 'PST': 'ppublish', 'SO': 'Anasthesiol Intensivmed Notfallmed Schmerzther. 2019 Mar;54(3):206-216. doi: 10.1055/a-0756-8263. Epub 2019 Mar 13.'}\n",
      "{'PMID': '30641614', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20200511', 'IS': '1439-4413 (Electronic) 0012-0472 (Linking)', 'VI': '143', 'IP': '21', 'DP': '2018 Oct', 'TI': '[Infectious Disease Consultations in Patients with Staphylococcus Aureus Bacteraemia - a Retrospective Observational Study at Jena University Hospital].', 'PG': 'e2', 'LID': '10.1055/a-0816-9947 [doi]', 'FAU': ['Kimmig, Aurelia', 'Weis, Sebastian', 'Hagel, Stefan', 'Forstner, Christina', 'Kesselmeier, Miriam', 'Pletz, Mathias W'], 'AU': ['Kimmig A', 'Weis S', 'Hagel S', 'Forstner C', 'Kesselmeier M', 'Pletz MW'], 'AD': ['Institut fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena.', 'Institut fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena.', 'Center for Sepsis Control and Care (CSCC), Universitatsklinikum Jena.', 'Klinik fur Anasthesie und Notfallmedizin, Universitatsklinikum Jena.', 'Institut fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena.', 'Center for Sepsis Control and Care (CSCC), Universitatsklinikum Jena.', 'Institut fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena.', 'Klinische Abteilung fur Infektionen und Tropenmedizin, Universitatsklinik fur Innere Medizin I, Medizinische Universitat Wien.', 'Center for Sepsis Control and Care (CSCC), Universitatsklinikum Jena.', 'Arbeitsgruppe Klinische Epidemiologie, CSCC, Universitatsklinikum Jena.', 'Institut fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena.', 'Center for Sepsis Control and Care (CSCC), Universitatsklinikum Jena.'], 'LA': ['ger'], 'PT': ['Journal Article', 'Published Erratum'], 'TT': 'Infektiologische Konsile bei Patienten mit Staphylococcus-aureus-Bakteriamie - eine retrospektive Beobachtungsstudie am Universitatsklinikum Jena.', 'DEP': '20190114', 'PL': 'Germany', 'TA': 'Dtsch Med Wochenschr', 'JT': 'Deutsche medizinische Wochenschrift (1946)', 'JID': '0006723', 'EFR': ['Dtsch Med Wochenschr. 2018 Oct;143(21):e179-e187. PMID: 30170325'], 'COIS': ['Disclosure The authors report no conflicts of interest in this work.'], 'EDAT': '2019/01/15 06:00', 'MHDA': '2019/01/15 06:01', 'CRDT': ['2019/01/15 06:00'], 'PHST': ['2019/01/15 06:00 [entrez]', '2019/01/15 06:00 [pubmed]', '2019/01/15 06:01 [medline]'], 'AID': ['10.1055/a-0816-9947 [doi]'], 'PST': 'ppublish', 'SO': 'Dtsch Med Wochenschr. 2018 Oct;143(21):e2. doi: 10.1055/a-0816-9947. Epub 2019 Jan 14.'}\n",
      "{'PMID': '30170325', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20190104', 'LR': '20190114', 'IS': '1439-4413 (Electronic) 0012-0472 (Linking)', 'VI': '143', 'IP': '21', 'DP': '2018 Oct', 'TI': '[Infectious Disease Consultations in Patients with Staphylococcus Aureus Bacteraemia - a Retrospective Observational Study at Jena University Hospital].', 'PG': 'e179-e187', 'LID': '10.1055/a-0653-7826 [doi]', 'FAU': ['Kimmig, Aurelia', 'Weis, Sebastian', 'Hagel, Stefan', 'Forstner, Christina', 'Kesselmeier, Miriam', 'Pletz, Mathias W'], 'AU': ['Kimmig A', 'Weis S', 'Hagel S', 'Forstner C', 'Kesselmeier M', 'Pletz MW'], 'AD': ['Institut fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena.', 'Institut fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena.', 'Center for Sepsis Control and Care (CSCC), Universitatsklinikum Jena.', 'Klinik fur Anasthesie und Notfallmedizin, Universitatsklinikum Jena.', 'Institut fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena.', 'Center for Sepsis Control and Care (CSCC), Universitatsklinikum Jena.', 'Institut fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena.', 'Klinische Abteilung fur Infektionen und Tropenmedizin, Universitatsklinik fur Innere Medizin I, Medizinische Universitat Wien.', 'Center for Sepsis Control and Care (CSCC), Universitatsklinikum Jena.', 'Arbeitsgruppe Klinische Epidemiologie, CSCC, Universitatsklinikum Jena.', 'Institut fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena.', 'Center for Sepsis Control and Care (CSCC), Universitatsklinikum Jena.'], 'LA': ['ger'], 'PT': ['Journal Article', 'Observational Study'], 'TT': 'Infektiologische Konsile bei Patienten mit Staphylococcus-aureus-Bakteriamie - eine retrospektive Beobachtungsstudie am Universitatsklinikum Jena.', 'DEP': '20180831', 'PL': 'Germany', 'TA': 'Dtsch Med Wochenschr', 'JT': 'Deutsche medizinische Wochenschrift (1946)', 'JID': '0006723', 'SB': 'IM', 'EIN': ['Dtsch Med Wochenschr. 2018 Oct;143(21):e2. PMID: 30641614'], 'MH': ['Aged', '*Bacteremia/epidemiology/therapy', 'Female', 'Germany/epidemiology', 'Hospitals, University', 'Humans', 'Male', 'Middle Aged', 'Referral and Consultation/*statistics & numerical data', 'Retrospective Studies', '*Staphylococcal Infections/epidemiology/therapy', '*Staphylococcus aureus'], 'COIS': ['AK und MK geben keine Interessenkonflikte an.SW hat Vortragshonorare von MSD und', 'Infectopharm erhalten.SH hat Vortragshonorare von Pfizer, MSD, Infectopharm und', 'Astra Zeneca erhalten.CF gibt an, Vortragshonorare von Pfizer, MSD, Basilea und', 'Gilead erhalten zu haben.MP hat an nationalen und internationalen Advisory-Boards', 'von Pfizer, Novartis, Basilea, Infectopharm und Cubist teilgenommen und', 'Vortragshonorare dieser Firmen erhalten. Das Integrierte Forschungs- und', 'Behandlungszentrum \"Sepsis und Sepsisfolgen\" am Universitatsklinikum Jena wird', 'durch das Bundesministerium fur Bildung und Forschung (BMBF, Forderkennzeichen', '01EO1502) gefordert.'], 'EDAT': '2018/09/01 06:00', 'MHDA': '2019/01/05 06:00', 'CRDT': ['2018/09/01 06:00'], 'PHST': ['2018/09/01 06:00 [pubmed]', '2019/01/05 06:00 [medline]', '2018/09/01 06:00 [entrez]'], 'AID': ['10.1055/a-0653-7826 [doi]'], 'PST': 'ppublish', 'SO': 'Dtsch Med Wochenschr. 2018 Oct;143(21):e179-e187. doi: 10.1055/a-0653-7826. Epub 2018 Aug 31.'}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'PMID': '28391236', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20180101', 'LR': '20190202', 'IS': '2044-6055 (Electronic) 2044-6055 (Linking)', 'VI': '7', 'IP': '4', 'DP': '2017 Apr 8', 'TI': 'Study on the utility of a statewide counselling programme for improving mortality outcomes of patients with Staphylococcus aureus bacteraemia in Thuringia (SUPPORT): a study protocol of a cluster-randomised crossover trial.', 'PG': 'e013976', 'LID': '10.1136/bmjopen-2016-013976 [doi]', 'AB': 'INTRODUCTION: Staphylococcus aureus bacteraemia (SAB) is a frequent infection with high mortality rates. It requires specific diagnostic and therapeutic management such as prolonged intravenous administration of antibiotics and aggressive search for and control of infectious sources. Underestimation of disease severity frequently results in delayed or inappropriate management of patients with SAB leading to increased mortality rates. According to observational studies, patient counselling by infectious disease consultants (IDC) improves survival and reduces the length of hospital stay as well as complication rates. In many countries, IDC are available only in some tertiary hospitals. In this trial, we aim to demonstrate that the outcome of patients with SAB in small and medium size hospitals that do not employ IDC can be improved by unsolicited ID phone counselling. The SUPPORT trial will be the first cluster-randomised controlled multicentre trial addressing this question. METHODS AND ANALYSIS: SUPPORT is a single-blinded, multicentre interventional, cluster-randomised, controlled crossover trial with a minimum of 15 centres that will include 250 patients with SAB who will receive unsolicited IDC counselling and 250 who will receive standard of care. Reporting of SAB will be conducted by an electronic real-time blood culture registry established for the German Federal state of Thuringia (ALERTSNet) or directly by participating centres in order to minimise time delay before counselling. Mortality, disease course and complications will be monitored for 90 days with 30-day all-cause mortality rates as the primary outcome. Generalised linear mixed modelling will be used to detect the difference between the intervention sequences. We expect improved outcome of patients with SAB after IDC. ETHICS AND DISSEMINATION: We obtained ethics approval from the Ethics committee of the Jena University Hospital and from the Ethics committee of the State Chamber of Physicians of Thuringia. Results will be published in a peer-reviewed journal and additionally disseminated through public media. TRIAL REGISTRATION NUMBER: DRKS00010135.', 'CI': ['Published by the BMJ Publishing Group Limited. For permission to use (where not', 'already granted under a licence) please go to', 'http://www.bmj.com/company/products-services/rights-and-licensing/.'], 'FAU': ['Weis, S', 'Hagel, S', 'Schmitz, R P H', 'Scherag, A', 'Brunkhorst, F M', 'Forstner, C', 'Loffler, B', 'Pletz, M W'], 'AU': ['Weis S', 'Hagel S', 'Schmitz RP', 'Scherag A', 'Brunkhorst FM', 'Forstner C', 'Loffler B', 'Pletz MW'], 'AD': ['Center for Infectious Disease and Infection Control, Jena University Hospital, Jena, Germany.', 'Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany.', 'Department of Anesthesiology and Intensive Care, Jena University Hospital, Jena, Germany.', 'Center for Infectious Disease and Infection Control, Jena University Hospital, Jena, Germany.', 'Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany.', 'Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany.', 'Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany.', 'Center for Clinical Studies, Jena University Hospital, Jena, Germany.', 'Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany.', 'Department of Anesthesiology and Intensive Care, Jena University Hospital, Jena, Germany.', 'Center for Clinical Studies, Jena University Hospital, Jena, Germany.', 'Center for Infectious Disease and Infection Control, Jena University Hospital, Jena, Germany.', 'Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.', 'Institute for Medical Microbiology, Jena University Hospital, Jena, Germany.', 'Center for Infectious Disease and Infection Control, Jena University Hospital, Jena, Germany.', 'Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany.'], 'LA': ['eng'], 'SI': ['DRKS/DRKS00010135'], 'PT': ['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', \"Research Support, Non-U.S. Gov't\"], 'DEP': '20170408', 'PL': 'England', 'TA': 'BMJ Open', 'JT': 'BMJ open', 'JID': '101552874', 'RN': ['0 (Anti-Bacterial Agents)'], 'SB': 'IM', 'MH': ['Administration, Intravenous', 'Anti-Bacterial Agents/therapeutic use', 'Clinical Protocols', 'Cluster Analysis', '*Counseling/methods', 'Cross-Over Studies', 'Germany/epidemiology', 'Humans', 'Patient Education as Topic', 'Program Evaluation', 'Quality Assurance, Health Care', 'Referral and Consultation', '*Staphylococcal Infections/drug therapy/epidemiology/prevention & control', 'Staphylococcus aureus/*drug effects', 'Telephone'], 'PMC': 'PMC5775453', 'OTO': ['NOTNLM'], 'OT': ['*Staphylococcus aureus bacteremia', '*infectious disease counseling', '*randomized controlled trial'], 'EDAT': '2017/04/10 06:00', 'MHDA': '2018/01/02 06:00', 'CRDT': ['2017/04/10 06:00'], 'PHST': ['2017/04/10 06:00 [entrez]', '2017/04/10 06:00 [pubmed]', '2018/01/02 06:00 [medline]'], 'AID': ['bmjopen-2016-013976 [pii]', '10.1136/bmjopen-2016-013976 [doi]'], 'PST': 'epublish', 'SO': 'BMJ Open. 2017 Apr 8;7(4):e013976. doi: 10.1136/bmjopen-2016-013976.'}\n",
      "{'PMID': '28378151', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20180315', 'LR': '20181113', 'IS': '2193-6226 (Electronic) 2193-6218 (Linking)', 'VI': '112', 'IP': '3', 'DP': '2017 Apr', 'TI': '[Antibiotic stewardship and Staphylococcus aureus Bacteremia].', 'PG': '192-198', 'LID': '10.1007/s00063-017-0270-4 [doi]', 'AB': 'Rates of antibiotic resistance are increasing worldwide and impact on the treatment of patients with bacterial infections. A broad and uncritical application in inpatient and outpatient settings as well as in agriculture has been recognized as the main driving force. Antibiotic stewardship (ABS) programs aim at countering this worrisome development using various direct interventions such as infectious disease counseling. Blood stream infections caused by Staphylococcus (S.) aureus are severe infections associated with high mortality rates. ABS interventions such as de-eskalation of the antibiotic regimen or application of narrow-spectrum beta-lactam antibiotics can significantly reduce mortality rates. In this review, we discuss the importance of ABS programs and infectious disease counseling for the treatment of S. aureus blood stream infection.', 'FAU': ['Weis, S', 'Kimmig, A', 'Hagel, S', 'Pletz, M W'], 'AU': ['Weis S', 'Kimmig A', 'Hagel S', 'Pletz MW'], 'AD': ['Zentrum fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena, Am Klinikum 1, 07740, Jena, Deutschland. sebastian.weis@med.uni-jena.de.', 'Center for Sepsis Control and Care, Universitatsklinikum Jena, Jena, Deutschland. sebastian.weis@med.uni-jena.de.', 'Klinik fur Anasthesiologie und Intensivmedizin, Universitatsklinikum Jena, Jena, Deutschland. sebastian.weis@med.uni-jena.de.', 'Zentrum fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena, Am Klinikum 1, 07740, Jena, Deutschland.', 'Zentrum fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena, Am Klinikum 1, 07740, Jena, Deutschland.', 'Center for Sepsis Control and Care, Universitatsklinikum Jena, Jena, Deutschland.', 'Zentrum fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena, Am Klinikum 1, 07740, Jena, Deutschland.', 'Center for Sepsis Control and Care, Universitatsklinikum Jena, Jena, Deutschland.'], 'LA': ['ger'], 'PT': ['Journal Article', 'Review'], 'TT': 'Antibiotic Stewardship am Beispiel der Staphylococcus aureus Bakteriamie.', 'DEP': '20170404', 'PL': 'Germany', 'TA': 'Med Klin Intensivmed Notfmed', 'JT': 'Medizinische Klinik, Intensivmedizin und Notfallmedizin', 'JID': '101575086', 'SB': 'IM', 'MH': ['*Antimicrobial Stewardship', 'Bacteremia/*drug therapy/mortality', 'Cross-Sectional Studies', '*Drug Resistance, Multiple, Bacterial', 'Germany', 'Humans', '*Methicillin-Resistant Staphylococcus aureus', '*Population Surveillance', 'Staphylococcal Infections/*drug therapy/mortality', 'Survival Rate'], 'OTO': ['NOTNLM'], 'OT': ['Blood culture', 'Drug resistance, bacterial', 'Infection', 'MRSA', 'Mortality'], 'EDAT': '2017/04/06 06:00', 'MHDA': '2018/03/16 06:00', 'CRDT': ['2017/04/06 06:00'], 'PHST': ['2017/01/06 00:00 [received]', '2017/02/13 00:00 [accepted]', '2017/04/06 06:00 [pubmed]', '2018/03/16 06:00 [medline]', '2017/04/06 06:00 [entrez]'], 'AID': ['10.1007/s00063-017-0270-4 [doi]', '10.1007/s00063-017-0270-4 [pii]'], 'PST': 'ppublish', 'SO': 'Med Klin Intensivmed Notfmed. 2017 Apr;112(3):192-198. doi: 10.1007/s00063-017-0270-4. Epub 2017 Apr 4.'}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'PMID': '26453841', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20160804', 'LR': '20181202', 'IS': '1532-2742 (Electronic) 0163-4453 (Linking)', 'VI': '72', 'IP': '1', 'DP': '2016 Jan', 'TI': 'Infectious disease consultation for Staphylococcus aureus bacteremia - A systematic review and meta-analysis.', 'PG': '19-28', 'LID': '10.1016/j.jinf.2015.09.037 [doi] S0163-4453(15)00315-1 [pii]', 'AB': 'OBJECTIVE: Mortality and morbidity of Staphylococcus aureus bacteremia (SAB) still remains considerably high. We aimed to evaluate the impact of infectious disease consultation (IDC) on the management and outcomes of patients with SAB. METHODS: We systematically searched 3 publication databases from inception to 31st May 2015 and reference lists of identified primary studies. RESULTS: Our search returned 2874 reports, of which 18 fulfilled the inclusion criteria, accounting for 5337 patients. Overall 30-day mortality was 19.95% [95% CI 14.37-27.02] with a significant difference in favour of the IDC group (12.39% vs 26.07%) with a relative risk (RR) of 0.53 [95% CI 0.43-0.65]. 90-day mortality and relapse risk for SAB were also reduced significantly with RRs of 0.77 [95% CI 0.64-0.92] and 0.62 [95% CI 0.39-0.99], respectively. Both, the appropriateness of antistaphylococcal agent and treatment duration was improved by IDC (RR 1.14 [95% CI 1.08-1.20] and 1.85 [95% CI 1.39-2.46], respectively). Follow-up blood cultures and echocardiography were performed more frequently following IDC (RR 1.35 [95% CI 1.25-1.46] and 1.98 [95% CI 1.66-2.37], respectively). CONCLUSIONS: Evidence-based clinical management enforced by IDC may improve outcome of patients with SAB. Well-designed cluster-randomized controlled trials are needed to confirm this finding from observational studies.', 'CI': ['Copyright (c) 2015 The British Infection Association. Published by Elsevier Ltd.', 'All rights reserved.'], 'FAU': ['Vogel, Monique', 'Schmitz, Roland P H', 'Hagel, Stefan', 'Pletz, Mathias W', 'Gagelmann, Nico', 'Scherag, Andre', 'Schlattmann, Peter', 'Brunkhorst, Frank M'], 'AU': ['Vogel M', 'Schmitz RP', 'Hagel S', 'Pletz MW', 'Gagelmann N', 'Scherag A', 'Schlattmann P', 'Brunkhorst FM'], 'AD': ['Paul Martini Sepsis Research Group, Department of Anaesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany.', 'Paul Martini Sepsis Research Group, Department of Anaesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany.', 'Integrated Research and Treatment Center, Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany; Center for Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany.', 'Integrated Research and Treatment Center, Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany; Center for Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany.', 'Paul Martini Sepsis Research Group, Department of Anaesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany.', 'Integrated Research and Treatment Center, Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany; Clinical Epidemiology, Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany.', 'Department of Medical Statistics, Computer Sciences and Documentation, Jena University Hospital, Jena, Germany.', 'Paul Martini Sepsis Research Group, Department of Anaesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany; Center for Clinical Studies, Jena University Hospital, Jena, Germany; Integrated Research and Treatment Center, Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany. Electronic address: frank.brunkhorst@med.uni-jena.de.'], 'LA': ['eng'], 'PT': ['Journal Article', 'Meta-Analysis', \"Research Support, Non-U.S. Gov't\", 'Review', 'Systematic Review'], 'DEP': '20151009', 'PL': 'England', 'TA': 'J Infect', 'JT': 'The Journal of infection', 'JID': '7908424', 'SB': 'IM', 'CIN': ['J Infect. 2018 Oct;77(4):349-356. PMID: 30067944'], 'MH': ['Aged', 'Bacteremia/*epidemiology/mortality', 'Child, Preschool', 'Female', 'Humans', 'Male', 'Middle Aged', 'Quality Indicators, Health Care/*statistics & numerical data', 'Referral and Consultation/*statistics & numerical data', 'Staphylococcal Infections/*epidemiology/mortality', '*Staphylococcus aureus'], 'OTO': ['NOTNLM'], 'OT': ['Bacteremia', 'Infectious disease medicine', 'Meta-analysis', 'Mortality', 'Quality of health care', 'Staphylococcus aureus'], 'EDAT': '2015/10/11 06:00', 'MHDA': '2016/08/05 06:00', 'CRDT': ['2015/10/11 06:00'], 'PHST': ['2015/07/06 00:00 [received]', '2015/09/28 00:00 [revised]', '2015/09/29 00:00 [accepted]', '2015/10/11 06:00 [entrez]', '2015/10/11 06:00 [pubmed]', '2016/08/05 06:00 [medline]'], 'AID': ['S0163-4453(15)00315-1 [pii]', '10.1016/j.jinf.2015.09.037 [doi]'], 'PST': 'ppublish', 'SO': 'J Infect. 2016 Jan;72(1):19-28. doi: 10.1016/j.jinf.2015.09.037. Epub 2015 Oct 9.'}\n",
      "{'PMID': '26452342', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20160711', 'LR': '20181113', 'IS': '1745-6215 (Electronic) 1745-6215 (Linking)', 'VI': '16', 'DP': '2015 Oct 9', 'TI': 'Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial.', 'PG': '450', 'LID': '10.1186/s13063-015-0973-x [doi]', 'AB': 'BACKGROUND: Current guidelines recommend that patients with Staphylococcus aureus bloodstream infection (SAB) are treated with long courses of intravenous antimicrobial therapy. This serves to avoid SAB-related complications such as relapses, local extension and distant metastatic foci. However, in certain clinical scenarios, the incidence of SAB-related complications is low. Patients with a low-risk for complications may thus benefit from an early switch to oral medication through earlier discharge and fewer complications of intravenous therapy. The major objective for the SABATO trial is to demonstrate that in patients with low-risk SAB a switch from intravenous to oral antimicrobial therapy (oral switch therapy, OST) is non-inferior to a conventional course of intravenous therapy (intravenous standard therapy, IST). METHODS/DESIGN: The trial is designed as randomized, parallel-group, observer-blinded, clinical non-inferiority trial. The primary endpoint is the occurrence of a SAB-related complication (relapsing SAB, deep-seated infection, and attributable mortality) within 90 days. Secondary endpoints are the length of hospital stay; 14-day, 30-day, and 90-day mortality; and complications of intravenous therapy. Patients with SAB who have received 5 to 7 full days of adequate intravenous antimicrobial therapy are eligible. Main exclusion criteria are polymicrobial bloodstream infection, signs and symptoms of complicated SAB (deep-seated infection, hematogenous dissemination, septic shock, and prolonged bacteremia), the presence of a non-removable foreign body, and severe comorbidity. Patients will receive either OST or IST with a protocol-approved antimicrobial and are followed up for 90 days. Four hundred thirty patients will be randomized 1:1 in two study arms. Efficacy regarding incidence of SAB-related complications is tested sequentially with a non-inferiority margin of 10 and 5 percentage points. DISCUSSION: The SABATO trial assesses whether early oral switch therapy is safe and effective for patients with low-risk SAB. Regardless of the result, this pragmatic trial will strongly influence the standard of care in SAB. TRIAL REGISTRATION: ClinicalTrials.gov NCT01792804 registered 13 February 2013; German Clinical trials register DRKS00004741 registered 4 October 2013, EudraCT 2013-000577-77 . First patient randomized on 20 December 2013.', 'FAU': ['Kaasch, Achim J', 'Fatkenheuer, Gerd', 'Prinz-Langenohl, Reinhild', 'Paulus, Ursula', 'Hellmich, Martin', 'Weiss, Verena', 'Jung, Norma', 'Rieg, Siegbert', 'Kern, Winfried V', 'Seifert, Harald'], 'AU': ['Kaasch AJ', 'Fatkenheuer G', 'Prinz-Langenohl R', 'Paulus U', 'Hellmich M', 'Weiss V', 'Jung N', 'Rieg S', 'Kern WV', 'Seifert H'], 'AD': ['Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Goldenfelsstr. 19-21, D-50935, Koln, Germany. achim.kaasch@uk-koeln.de.', 'Department I of Internal Medicine, University Hospital of Cologne, 50924, Cologne, Germany. g.faetkenheuer@uni-koeln.de.', 'German Centre for Infection Research (DZIF), partner site Bonn-Cologne, Germany. g.faetkenheuer@uni-koeln.de.', 'Clinical Trial Center Cologne, University of Cologne, 50924, Cologne, Germany. reinhild.prinz-langenohl@uk-koeln.de.', 'Clinical Trial Center Cologne, University of Cologne, 50924, Cologne, Germany. ursula.paulus@uk-koeln.de.', 'Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Kerpener Strasse 62, 50924, Cologne, Germany. martin.hellmich@uni-koeln.de.', 'Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Kerpener Strasse 62, 50924, Cologne, Germany. verena.weiss@uni-koeln.de.', 'Department I of Internal Medicine, University Hospital of Cologne, 50924, Cologne, Germany. norma.jung@uk-koeln.de.', 'Department of Medicine, Center for Infectious Diseases and Travel Medicine, University Medical Center Freiburg, Hugstetter Strasse 55, 79106, Freiburg, Germany. siegbert.rieg@uniklinik-freiburg.de.', 'Department of Medicine, Center for Infectious Diseases and Travel Medicine, University Medical Center Freiburg, Hugstetter Strasse 55, 79106, Freiburg, Germany. winfried.kern@uniklinik-freiburg.de.', 'Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Goldenfelsstr. 19-21, D-50935, Koln, Germany. harald.seifert@uni-koeln.de.', 'German Centre for Infection Research (DZIF), partner site Bonn-Cologne, Germany. harald.seifert@uni-koeln.de.'], 'CN': ['SABATO trial group (with linked authorship to the individuals in the', 'Acknowledgements section)'], 'LA': ['eng'], 'SI': ['DRKS/DRKS00004741', 'EudraCT/EUDRACT2013-000577-77', 'ClinicalTrials.gov/NCT01792804'], 'PT': ['Journal Article', 'Multicenter Study', 'Pragmatic Clinical Trial', 'Randomized Controlled Trial', \"Research Support, Non-U.S. Gov't\"], 'DEP': '20151009', 'PL': 'England', 'TA': 'Trials', 'JT': 'Trials', 'JID': '101263253', 'RN': ['0 (Anti-Bacterial Agents)'], 'SB': 'IM', 'MH': ['Administration, Intravenous', 'Administration, Oral', 'Anti-Bacterial Agents/*administration & dosage/adverse effects', 'Bacteremia/diagnosis/*drug therapy/microbiology/mortality', 'Clinical Protocols', 'Disease Progression', 'Europe', 'Humans', 'Recurrence', 'Research Design', 'Risk Factors', 'Staphylococcal Infections/diagnosis/*drug therapy/microbiology/mortality', 'Staphylococcus aureus/*drug effects/isolation & purification', 'Time Factors', 'Treatment Outcome'], 'PMC': 'PMC4600306', 'IR': ['Fatkenheuer G', 'Jung N', 'Kaasch AJ', 'Seifert H', 'Hellmich M', 'Weiss V', 'Lewalter K', 'Lemmen S', 'Stijnis C', 'van der Meer J', 'Soriano A', 'Ruiz LM', 'Arasteh K', 'Stocker H', 'Kluytmans J', 'Veenemans J', 'Brodt HR', 'Stephan C', 'Wolf T', 'Kessel J', 'Kern WV', 'Rieg S', 'Joost I', 'Sinha B', 'van Assen S', 'Wilting K', 'Welte T', 'Molgen C', 'Brunkhorst JF', 'Pletz M', 'Hagel S', 'Becker C', 'Frieling T', 'Kosters K', 'Reuter S', 'Hsiao M', 'Rupp J', 'Dalhoff K', 'Turner D', 'Snape S', 'Crusz S', 'Venkatesan P', 'Salzberger B', 'Hanses F', 'Rodriguez-Bano J', 'Mendez AV', 'Cortes LE', 'Cisneros JM', 'Navarro-Amuedo MD', 'Bonten M', 'Oosterheert JJ', 'Ekkelenkamp M'], 'FIR': ['Fatkenheuer, Gerd', 'Jung, Norma', 'Kaasch, Achim J', 'Seifert, Harald', 'Hellmich, Martin', 'Weiss, Verena', 'Lewalter, Karl', 'Lemmen, Sebastian', 'Stijnis, Cornelis', 'van der Meer, Jan', 'Soriano, Alex', 'Ruiz, Laura Morata', 'Arasteh, Keikawus', 'Stocker, Hartmut', 'Kluytmans, Jan', 'Veenemans, Jacobien', 'Brodt, Hans-Reinhard', 'Stephan, Christoph', 'Wolf, Timo', 'Kessel, Johanna', 'Kern, Winfried V', 'Rieg, Siegbert', 'Joost, Insa', 'Sinha, Bhanu', 'van Assen, Sander', 'Wilting, Kasper', 'Welte, Tobias', 'Molgen, Christiane', 'Brunkhorst, Julia Freise Frank', 'Pletz, Mathias', 'Hagel, Stefan', 'Becker, Christian', 'Frieling, Thomas', 'Kosters, Katrin', 'Reuter, Stefan', 'Hsiao, Mikai', 'Rupp, Jan', 'Dalhoff, Klaus', 'Turner, David', 'Snape, Susan', 'Crusz, Shanika', 'Venkatesan, Pradhib', 'Salzberger, Bernd', 'Hanses, Frank', 'Rodriguez-Bano, Jesus', 'Mendez, Adoracion Valiente', 'Cortes, Luis Eduardo Lopez', 'Cisneros, Jose Miguel', 'Navarro-Amuedo, Maria Dolores', 'Bonten, Marc', 'Oosterheert, Jan Jelrik', 'Ekkelenkamp, Miquel'], 'EDAT': '2015/10/11 06:00', 'MHDA': '2016/07/12 06:00', 'CRDT': ['2015/10/11 06:00'], 'PHST': ['2014/12/22 00:00 [received]', '2015/09/23 00:00 [accepted]', '2015/10/11 06:00 [entrez]', '2015/10/11 06:00 [pubmed]', '2016/07/12 06:00 [medline]'], 'AID': ['10.1186/s13063-015-0973-x [doi]', '10.1186/s13063-015-0973-x [pii]'], 'PST': 'epublish', 'SO': 'Trials. 2015 Oct 9;16:450. doi: 10.1186/s13063-015-0973-x.'}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'PMID': '26275448', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20161214', 'LR': '20191210', 'IS': '1439-0973 (Electronic) 0300-8126 (Linking)', 'VI': '44', 'IP': '2', 'DP': '2016 Apr', 'TI': 'Biomarker candidates for the detection of an infectious etiology of febrile neutropenia.', 'PG': '175-86', 'LID': '10.1007/s15010-015-0830-6 [doi]', 'AB': 'PURPOSE: Infections and subsequent septicemia are major complications in neutropenic patients with hematological malignancies. Here, we identify biomarker candidates for the early detection of an infectious origin, and monitoring of febrile neutropenia (FN). METHODS: Proteome, metabolome, and conventional biomarkers from 20 patients with febrile neutropenia without proven infection (FNPI) were compared to 28 patients with proven infection, including 17 patients with bacteremia. RESULTS: Three peptides (mass to charge ratio 1017.4-1057.3; p-values 0.011-0.024), six proteins (mass to charge ratio 6881-17,215; p-values 0.002-0.004), and six phosphatidylcholines (p-values 0.007-0.037) were identified that differed in FNPI patients compared to patients with infection or bacteremia. Seven of these marker candidates discriminated FNPI from infection at fever onset with higher sensitivity and specificity (ROC-AUC 0.688-0.824) than conventional biomarkers i.e., procalcitonin, C-reactive protein, or interleukin-6 (ROC-AUC 0.535-0.672). In a post hoc analysis, monitoring the time course of four lysophosphatidylcholines, threonine, and tryptophan allowed for discrimination of patients with or without resolution of FN (ROC-AUC 0.648-0.919) with higher accuracy compared to conventional markers (ROC-AUC 0.514-0.871). CONCLUSIONS: Twenty-one promising biomarker candidates for the early detection of an infectious origin or for monitoring the course of FN were found which might overcome known shortcomings of conventional markers.', 'FAU': ['Richter, Martin E', 'Neugebauer, Sophie', 'Engelmann, Falco', 'Hagel, Stefan', 'Ludewig, Katrin', 'La Rosee, Paul', 'Sayer, Herbert G', 'Hochhaus, Andreas', 'von Lilienfeld-Toal, Marie', 'Bretschneider, Tom', 'Pausch, Christine', 'Engel, Christoph', 'Brunkhorst, Frank M', 'Kiehntopf, Michael'], 'AU': ['Richter ME', 'Neugebauer S', 'Engelmann F', 'Hagel S', 'Ludewig K', 'La Rosee P', 'Sayer HG', 'Hochhaus A', 'von Lilienfeld-Toal M', 'Bretschneider T', 'Pausch C', 'Engel C', 'Brunkhorst FM', 'Kiehntopf M'], 'AD': ['Institut fur Klinische Chemie und Laboratoriumsdiagnostik, Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany.', 'Integriertes Forschungs- und Behandlungszentrum Sepsis und Sepsisfolgen (CSCC), Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany.', 'Institut fur Klinische Chemie und Laboratoriumsdiagnostik, Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany.', 'Integriertes Forschungs- und Behandlungszentrum Sepsis und Sepsisfolgen (CSCC), Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany.', 'Institut fur Klinische Chemie und Laboratoriumsdiagnostik, Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany.', 'Integriertes Forschungs- und Behandlungszentrum Sepsis und Sepsisfolgen (CSCC), Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany.', 'Zentrum fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany.', 'Klinik fur Innere Medizin IV (Gastroenterologie, Hepatologie, Infektiologie), Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany.', 'Integriertes Forschungs- und Behandlungszentrum Sepsis und Sepsisfolgen (CSCC), Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany.', 'Integriertes Forschungs- und Behandlungszentrum Sepsis und Sepsisfolgen (CSCC), Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany.', 'Klinik fur Innere Medizin II, Abt. Hamatologie und Intern. Onkologie, Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany.', 'Integriertes Forschungs- und Behandlungszentrum Sepsis und Sepsisfolgen (CSCC), Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany.', 'Klinik fur Innere Medizin II, Abt. Hamatologie und Intern. Onkologie, Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany.', '4. Medizinische Klinik (Hamatologie und internistische Onkologie, Hamostaseologie), HELIOS Klinikum Erfurt, Nordhauser Strasse 74, 99089, Erfurt, Germany.', 'Integriertes Forschungs- und Behandlungszentrum Sepsis und Sepsisfolgen (CSCC), Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany.', 'Klinik fur Innere Medizin II, Abt. Hamatologie und Intern. Onkologie, Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany.', 'Integriertes Forschungs- und Behandlungszentrum Sepsis und Sepsisfolgen (CSCC), Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany.', 'Klinik fur Innere Medizin II, Abt. Hamatologie und Intern. Onkologie, Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany.', 'Leibniz Institut fur Naturstoff-Forschung und Infektionsbiologie, Hans-Knoll-Institut, Adolf-Reichwein-Strasse 23, 07745, Jena, Germany.', 'Integriertes Forschungs- und Behandlungszentrum Sepsis und Sepsisfolgen (CSCC), Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany.', 'Institut fur Medizinische Informatik, Statistik und Epidemiologie, Universitat Leipzig, Hartelstrasse 16-18, 04107, Leipzig, Germany.', 'Institut fur Medizinische Informatik, Statistik und Epidemiologie, Universitat Leipzig, Hartelstrasse 16-18, 04107, Leipzig, Germany.', 'Zentrum fur Klinische Studien, Universitatsklinikum Jena, Salvador-Allende-Platz 27, 07747, Jena, Germany.', 'Institut fur Klinische Chemie und Laboratoriumsdiagnostik, Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany. michael.kiehntopf@med.uni-jena.de.', 'Integriertes Forschungs- und Behandlungszentrum Sepsis und Sepsisfolgen (CSCC), Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany. michael.kiehntopf@med.uni-jena.de.'], 'LA': ['eng'], 'PT': ['Evaluation Study', 'Journal Article', \"Research Support, Non-U.S. Gov't\"], 'DEP': '20150815', 'PL': 'Germany', 'TA': 'Infection', 'JT': 'Infection', 'JID': '0365307', 'RN': ['0 (Biomarkers)'], 'SB': 'IM', 'MH': ['Adult', 'Aged', 'Aged, 80 and over', 'Biomarkers/*blood', 'Communicable Diseases/*diagnosis', 'Early Diagnosis', 'Febrile Neutropenia/*diagnosis', 'Female', 'Hematologic Neoplasms/complications', 'Humans', 'Male', 'Middle Aged', 'Sensitivity and Specificity', 'Young Adult'], 'OTO': ['NOTNLM'], 'OT': ['Biomarkers', 'Febrile neutropenia', 'Infection', 'Metabolome', 'Proteome'], 'EDAT': '2015/08/16 06:00', 'MHDA': '2016/12/15 06:00', 'CRDT': ['2015/08/16 06:00'], 'PHST': ['2015/05/26 00:00 [received]', '2015/07/31 00:00 [accepted]', '2015/08/16 06:00 [entrez]', '2015/08/16 06:00 [pubmed]', '2016/12/15 06:00 [medline]'], 'AID': ['10.1007/s15010-015-0830-6 [doi]', '10.1007/s15010-015-0830-6 [pii]'], 'PST': 'ppublish', 'SO': 'Infection. 2016 Apr;44(2):175-86. doi: 10.1007/s15010-015-0830-6. Epub 2015 Aug 15.'}\n",
      "{'PMID': '26115133', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20160426', 'LR': '20170420', 'IS': '1439-4413 (Electronic) 0012-0472 (Linking)', 'VI': '140', 'IP': '13', 'DP': '2015 Jun', 'TI': '[Staphylococcus aureus bacteremia - a distinct entity].', 'PG': '982-9', 'LID': '10.1055/s-0041-102453 [doi]', 'AB': 'Bacteremia caused by Methicillin-sensitive (MSSA) and Methicillin-resistant (MRSA) Staphyloccus aureus strains are common and severe infections associated with high mortality rates and specific characteristics in disease course, complications and therapy. In this review, we discuss current recommendations for the diagnosis and treatment of MSSA and MRSA bloodstream infections. We also highlight why infectious disease consultation improves the treatment and outcome of patients with SAB and should be considered as a standard of care.', 'CI': ['(c) Georg Thieme Verlag KG Stuttgart . New York.'], 'FAU': ['Weis, Sebastian', 'Kaasch, Achim J', 'Rieg, Siegbert', 'Loffler, Bettina', 'Hagel, Stefan', 'Forstner, Christina', 'Brunkhorst, Frank M', 'Pletz, Mathias W'], 'AU': ['Weis S', 'Kaasch AJ', 'Rieg S', 'Loffler B', 'Hagel S', 'Forstner C', 'Brunkhorst FM', 'Pletz MW'], 'AD': ['Zentrum fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena.', 'Institut fur Medizinische Mikrobiologie, Immunologie und Hygiene, Universitatsklinikum Koln.', 'Abteilung Infektiologie, Klinik fur Innere Medizin II, Universitatsklinikum Freiburg.', 'Institut fur Medizinische Mikrobiologie, Universitatsklinikum Jena.', 'Zentrum fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena.', 'Zentrum fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena.', 'Zentrum fur klinische Studien, Universitatsklinikum Jena.', 'Zentrum fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena.'], 'LA': ['ger'], 'PT': ['English Abstract', 'Journal Article', 'Review'], 'TT': 'Staphylococcus-aureus-Bakteriamie - eine eigene Entitat.', 'DEP': '20150626', 'PL': 'Germany', 'TA': 'Dtsch Med Wochenschr', 'JT': 'Deutsche medizinische Wochenschrift (1946)', 'JID': '0006723', 'RN': ['0 (Anti-Bacterial Agents)'], 'SB': 'IM', 'CIN': ['Dtsch Med Wochenschr. 2016 May;141(10 ):674. PMID: 27176053', 'Dtsch Med Wochenschr. 2016 May;141(10 ):674. PMID: 27176054'], 'MH': ['Anti-Bacterial Agents/*therapeutic use', 'Bacteremia/*drug therapy/mortality/transmission', 'Cooperative Behavior', 'Cross Infection/*drug therapy/mortality/transmission', 'Humans', 'Interdisciplinary Communication', 'Methicillin-Resistant Staphylococcus aureus/*drug effects', 'Referral and Consultation', 'Risk Factors', 'Staphylococcal Infections/*drug therapy/mortality/transmission', 'Survival Rate'], 'EDAT': '2015/06/27 06:00', 'MHDA': '2016/04/27 06:00', 'CRDT': ['2015/06/27 06:00'], 'PHST': ['2015/06/27 06:00 [entrez]', '2015/06/27 06:00 [pubmed]', '2016/04/27 06:00 [medline]'], 'AID': ['10.1055/s-0041-102453 [doi]'], 'PST': 'ppublish', 'SO': 'Dtsch Med Wochenschr. 2015 Jun;140(13):982-9. doi: 10.1055/s-0041-102453. Epub 2015 Jun 26.'}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'PMID': '23478795', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20130930', 'LR': '20181113', 'IS': '1432-1289 (Electronic) 0020-9554 (Linking)', 'VI': '54', 'IP': '4', 'DP': '2013 Apr', 'TI': '[Bacteremia and sepsis].', 'PG': '399-407', 'LID': '10.1007/s00108-012-3185-4 [doi]', 'AB': 'Bacteremia and sepsis are common problems in clinical practice. Bacteremia is the presence of bacteria in the blood, hence a microbiological finding. Sepsis is a clinical diagnosis needing further specification regarding focus of infection and etiologic pathogen, whereupon clinicians, epidemiologists and microbiologists apply different definitions and terminology. Knowing these differences is important when reading and interpreting the literature. Studies show a pan-European increase in the rate of bacteremia, both Gram-negative and Gram-positive. Reasons for this are an increase in invasive diagnostics and therapy, going along with increasing age of patients. Bacteremic infections are frequently healthcare related. This article illustrates recent aspects in diagnosis and therapy of sepsis and bacteremia.', 'FAU': ['Hagel, S', 'Pletz, M W', 'Brunkhorst, F M', 'Seifert, H', 'Kern, W V'], 'AU': ['Hagel S', 'Pletz MW', 'Brunkhorst FM', 'Seifert H', 'Kern WV'], 'AD': ['Zentrum fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena, Erlanger Allee 101, 07740 Jena. stefan.hagel@med.uni-jena.de'], 'LA': ['ger'], 'PT': ['English Abstract', 'Journal Article'], 'TT': 'Bakteriamie und Sepsis.', 'PL': 'Germany', 'TA': 'Internist (Berl)', 'JT': 'Der Internist', 'JID': '0264620', 'RN': ['0 (Anti-Bacterial Agents)'], 'SB': 'IM', 'MH': ['Anti-Bacterial Agents/*therapeutic use', 'Bacteremia/complications/*diagnosis/*drug therapy', 'Humans', 'Prevalence', 'Sepsis/*diagnosis/*drug therapy/etiology'], 'EDAT': '2013/03/13 06:00', 'MHDA': '2013/10/01 06:00', 'CRDT': ['2013/03/13 06:00'], 'PHST': ['2013/03/13 06:00 [entrez]', '2013/03/13 06:00 [pubmed]', '2013/10/01 06:00 [medline]'], 'AID': ['10.1007/s00108-012-3185-4 [doi]'], 'PST': 'ppublish', 'SO': 'Internist (Berl). 2013 Apr;54(4):399-407. doi: 10.1007/s00108-012-3185-4.'}\n"
     ]
    }
   ],
   "source": [
    "if id_quantity > 100000:\n",
    "    rounds = round(id_quantity/100000)\n",
    "    retmax=100*1000\n",
    "else:\n",
    "    rounds = 1\n",
    "    retmax = id_quantity\n",
    "\n",
    "retstart=0\n",
    "abstracts=[]\n",
    "\n",
    "for round in range(0,rounds):\n",
    "    \n",
    "    search = Entrez.esearch(db=\"pubmed\", retmax=retmax, term=term)\n",
    "    \n",
    "    id_quantity -= retmax\n",
    "    retstart += retmax\n",
    "    if id_quantity < 100000:\n",
    "        retmax = id_quantity\n",
    "    \n",
    "    result = Entrez.read(search)\n",
    "       \n",
    "for single_id in result['IdList']:\n",
    "    search = Entrez.efetch(db=\"pubmed\", id=single_id, rettype=\"medline\", retmode=\"text\")\n",
    "    record = list(Medline.parse(search))\n",
    "    record = dict(record[0])\n",
    "    print(record)\n",
    "    try:\n",
    "        pmid = record[\"PMID\"]\n",
    "        date = record[\"DP\"]\n",
    "        record = record[\"AB\"]\n",
    "        abstracts.append([date,record])\n",
    "    except KeyError:\n",
    "        pass\n",
    "\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
